Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas S Heitmann

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|June 17, 2020
Fc gamma receptor expression serves as prognostic and diagnostic factor in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
BMJ Open|October 17, 2020
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinomaJonas S Heitmann, Juliane S Walz, Martin Pflügler, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 16, 2022
Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohortChristian M Tegeler, Tatjana Bilich, Yacine Maringer, et al.
Cancers|July 12, 2020
HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell TransplantationMalte Roerden, Annika Nelde, Jonas S Heitmann, et al.
Annals of Hematology|January 23, 2020
Identification of CD318 (CDCP1) as novel prognostic marker in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Cancers|May 14, 2022
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer PatientsChristian M Tegeler, Jonas Scheid, Hans-Georg Rammensee, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2022
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitroJoseph Kauer, Melanie Märklin, Martin Pflügler, et al.
Frontiers in Immunology|May 1, 2023
IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancerMartina S Lutz, Latifa Zekri, Laura Weßling, et al.
Cancers|September 26, 2020
Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic LeukemiaClaudia Tandler, Moritz Schmidt, Jonas S Heitmann, et al.
Scientific Reports|December 5, 2019
CD105 (Endoglin) as negative prognostic factor in AMLJoseph Kauer, Karolin Schwartz, Claudia Tandler, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|June 17, 2020
Fc gamma receptor expression serves as prognostic and diagnostic factor in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
BMJ Open|October 17, 2020
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinomaJonas S Heitmann, Juliane S Walz, Martin Pflügler, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 16, 2022
Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohortChristian M Tegeler, Tatjana Bilich, Yacine Maringer, et al.
Cancers|July 12, 2020
HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell TransplantationMalte Roerden, Annika Nelde, Jonas S Heitmann, et al.
Annals of Hematology|January 23, 2020
Identification of CD318 (CDCP1) as novel prognostic marker in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Cancers|May 14, 2022
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer PatientsChristian M Tegeler, Jonas Scheid, Hans-Georg Rammensee, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2022
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitroJoseph Kauer, Melanie Märklin, Martin Pflügler, et al.
Frontiers in Immunology|May 1, 2023
IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancerMartina S Lutz, Latifa Zekri, Laura Weßling, et al.
Cancers|September 26, 2020
Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic LeukemiaClaudia Tandler, Moritz Schmidt, Jonas S Heitmann, et al.
Scientific Reports|December 5, 2019
CD105 (Endoglin) as negative prognostic factor in AMLJoseph Kauer, Karolin Schwartz, Claudia Tandler, et al.
Pageof 7